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Abstract
Major cause of death in patients with cystic fibrosis (CF) is colonization with Staphylococcus aureus
and Pseudomonas aeruginosa. The wide phenotypic variation in CF patients suggests that genes
other than the cystic fibrosis transmembrane conductance regulator (CFTR) gene modify the disease.
The 8.1 ancestral haplotype (8.1AH) in main histocompatibility complex is associated with alterations
of the immune response. To study the influence of carriage of 8.1AH on frequency and onset of
colonization in CF patients, DNA samples of 72 CF patients (39 homozygous and 33 heterozygous for
DF508) were genotyped for member alleles of the 8.1AH: HLA-DQB1*0201, HLA-DRB1*0301, receptor
for advanced glycation end products (AGER) 429C, HSP70-2 1267G (HSP70-2G) and tumor
necrosis factor-a (TNF-a) 308A (TNF2). Colonization was verified by regular clinical and
bacteriological screening. Frequency of colonization was significantly (P 5 0.012) lower in the 8.1AH
carriers; age, gender and DF508 genotype-adjusted odds ratio to be colonized of the carriers versus
non-carriers was 0.112 (0.024–0.520). According to survival analysis, patients with 8.1AH had
significantly (P < 0.0001) longer colonization-free period compared with non-carriers. Our novel
observations demonstrate that the 8.1AH is associated with delayed onset of colonization in CF,
presumably by influencing defense mechanisms against infections.
Introduction
Cystic fibrosis (CF), the most common lethal autosomal
recessive genetic disorder in the Caucasian population, is
caused by mutations in a 230-kb gene on chromosome 7
encoding a 1480 amino acid polypeptide, named cystic
fibrosis transmembrane conductance regulator (CFTR), which
functions as anion channel in epithelial membranes (1). The
most frequent mutation is caused by deletion of phenylalanine
at position 508 (DF508). The vast majority of CF patients suffer
from chronic bacterial lung infection/inflammation caused
most frequently by Staphylococcus aureus and/or Pseudo-
monas aeruginosa. Such infection is also called coloniza-
tion and is responsible for the reduced life expectancy of CF
patients (2). However, the wide phenotypic variation in patients
homozygous for DF508 (3–8) suggests that genes other than
CFTR, environmental factors or both modify development, pro-
gression and severity of the disease. Therefore, the onset and
severity of pulmonary disease are not easily predicted (9, 10).
Therefore, identification of factors that may modify the course
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of CF is of utmost importance (1). Most of the candidate modi-
fier genes that may affect the clinical course of CF, such as
transforming growth factor b (11), mannose binding lectin (12,
13), nitric oxide synthase 1 (14) or genes localized in the major
histocompatibility complex (MHC) (15, 16) and tumor necrosis
factor-a (TNF-a) (3–8) play important roles in the innate or ac-
quired immune response.
There is vast controversy in the role of several modifier gene
candidates in CF, since correlations with the clinical status of CF
patients remain doubtful. The TNF-a308A (TNF2) allele is
a good example for the conflicting data between pulmonary
phenotype and disease severity. Hull and Thomson (6) found
the TNF2 allele to be associated with a decrease in forced
expiratory volume1. Other studies could not confirm associ-
ation with any markers of disease severity (7, 8). In all of these
cases, separate single-nucleotide polymorphisms (SNPs) were
studied, without the context of a haplotype. Haplotype differ-
ences mean that discrepancies may arise from the differences
in the distribution of certain alleles in different populations. In
addition, the interaction of possible modifier genes with envir-
onmental factors such as exposure to tobacco smoke may also
contribute to diversity in the clinical picture of the disease (17).
The term ‘ancestral haplotype’ defines highly conserved
haplotype—blocks of highly conserved genomic sequences—
derived from a common remote ancestor (18). One of these
ancestral haplotypes (AHs), called 8.1AH is encoded in the
MHC region on the short arm of chromosome 6 (19). 8.1AH
Individuals have altered cytokine profile, increased TNF-a pro-
duction, high titers of autoantibodies and circulating immune
complexes, which are thought to be beneficial in response to
infections. However, 8.1AH may lead to the development of
autoimmune diseases as a long-term side effect (20, 21). The
8.1AH consists of, among others, the HLA-A1, B8, Cw7,
DQB1*0201 (DQ2), DRB1*0301 (DR3), DQA1*0501, TNF2 and
C4A*Q0 alleles (18, 20, 21). According to a study of Price et al.
(18), receptor for advanced glycation end products (AGER)
429C and HSP70-2G (HSP70-2 1267 G) alleles are
candidate members of the 8.1AH.
We hypothesized that the 8.1AH has a role in chronic in-
fections (colonization) in CF. Therefore, we determined HLA-
DQB1, HLA-DRB1, TNF-a308 G > A, AGER 429 T > C as
well as HSP70-2 1267 A > G polymorphisms in 72 CF
patients (39 patients were homozygous and 33 patients were
heterozygous for DF508) and TNF-a308 G > A, AGER 429
T > C and HSP70-2 1267 A > G polymorphisms in 139
healthy controls. All patients registered at seven Hungarian CF
centers with available data about the onset of colonization
were included in the study.
Methods
Study population
We have studied 39 CF patients, homozygous for DF508, aged
1–28 years (median age 11 years, 25–75%: 4–18 years), and
33 CF patients heterozygous for DF508, aged 3–35 years
(median age 12 years, 25–75%: 6.5–17.5 years), attending
seven Hungarian CF centers. In all 72 cases, diagnosis of CF
has been proven both by typical clinical features, abnormal
sweat test, and genetic tests, i.e. mutations in the CFTR gene.
Lung colonization with P. aeruginosa and S. aureus was
investigated by routine microbiological methods collected at
least once or twice a year during center visits. Colonization
was defined from the first positive recorded culture provided if
stayed positive subsequently. A patient with annual throat cul-
ture was considered non-colonized if such cultures were not
persistently positive for a given pathogen. All colonized patients
were colonized with P. aeruginosa and/or S. aureus; no coloniza-
tion with Burkholderia, Stenotrophomonas, Achromobacter or
Nontuberculous mycobacteria was detected in the studied
population. All study patients were followed from at least the
age of onset of colonization. Four patients were vaccinated
against P. aeruginosa, none of them were colonized and none
of them carriedy the 8.1AH. Treatment and care of CF patients
are determined by national guidelines in every Hungarian CF
center. Written consent was received from each patient for
the use of their DNA samples in this study. The procedures fol-
lowed were in accordance with the ethical standards of the
Hungarian Ethical Committee on human experimentation and
with the Helsinki Declaration of 1975, as revised in 1983. Written
informed consent was received from patients for the use of
their DNA samples in this study. Deceased patients were not
included in the study.
139 healthy persons (56 males, 83 females, 29.46 3.9 years
old) who volunteered for the study served as controls.
Genotyping methods
Genotyping of the following alleles, TNF-a308 (22), AGER
429 (23) and HSP70-2 (24, 25) from MHC III region and HLA-
DQB1 (Olerup SSP TM DQ kit, Olerup SSP AB, Saltsjo¨baden,
Sweden) and HLA-DRB1 (INNO-LiPA HLA-DRB1 Plus kit,
Innogenetics, Ghent, Belgium) from the MHC II region was
carried out by sequence-specific priming–PCR (HLA-DQB1,
TNF-a308), sequence-specific oligonucleotide probes–PCR
(HLA-DRB1) and PCR–restriction fragment length polymor-
phism (AGER 429, HSP70-2) in the genomic DNA of CF
patients. Carriage of the 8.1AH haplotype was considered
when AGER429C, HSP70-2G, TNF308A, HLA-DRB1*0301
and HLA-DQB*0201 were carried simultaneously.
Statistical analysis
For statistical evaluation, GraphPad Prism 4.00 for Windows
software package was used (GraphPad Software, San Diego,
CA, USA, http://www.graphpad.com). Significance was con-
sidered at P < 0.05. Power analysis was performed by using
the GraphPad StatMate software (GraphPad Software). All
differences found to be significant at the univariate analysis
were checked by multivariate logistic regression models.
Length of colonization-free period between groups of the
patients was compared by survival curve analysis using the
Mantel–Haenszel log rank test for comparison. Ages of
patients were compared by Mann–Whitney test.
Results
Occurrence of the MHC III marker alleles and haplotypes
of the 8.1AH in CF patients and normal population
The frequency of three 8.1AH marker alleles encoded in the
MHC III (central region of MHC), TNF 308A (TNF2), HSP70-2
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1267G (HSP70-2G) and the AGER 429C was determined in
72 patients with CF. Since we have not determined the
frequencies of the MHC II marker alleles [HLA-DQ2 and HLA-
DR3 (17)] in our control group yet, we could not perform the
comparison for these alleles (Table 1).
No significant differences between the whole group of CF
patients and healthy controls were found in the frequency of
either 8.1AH marker allele or haplotypes. The patients were
divided into two groups, those who were colonized till the time
of the study (n = 44) and those who were not (n = 28). Dramatic
differences were found in the case of non-colonized patients:
the frequency of all but one (HSP70-2G) alleles and all but
one haplotypes tested was significantly higher among these
patients than in healthy controls. The highest difference was
found with the TNF2-HSP70-2-G-AGER 429C haplotype, it
occurred more than three times more frequently among the
non-colonized patients than among the controls. By contrast,
the frequency of neither alleles nor haplotypes tested sig-
nificantly differ between the groups of already colonized
patients and healthy controls (Table 1).
Since the age of the non-colonized CF patients (9.8 6 6.2
years) was substantially lower than that of the controls (29.46
3.9 years old), we performed an age- and gender-adjusted
multiple regression analysis, and found that the difference
between the two groups in the TNF2-HSP70-2-G-AGER
429C haplotype remained significant (P = 0.031) after
adjustment.
CF population stratified according to carriers and
non-carriers of the 8.1AH—modifier effect of the 8.1AH
on colonization
The basic clinical characteristics of the study population are
presented in Table 2. No significant difference according to
the carriage of the 8.1AH was found in gender, median age
and proportion of DF508 homozygotes and heterozygotes
in the 72 CF patients. DF508 heterozygous patients carrying
the 8.1AH were slightly but not significantly (P = 0.086) older
than non-carriers.
By contrast, we found marked differences between carriers
and non-carriers of the 8.1AH in the percentages of colonized
and non-colonized patients as well as in the age at
colonization (Table 2). The median age at colonization was
significantly higher and the proportion of patients colonized
with P. aeruginosa and/or S. aureus was significantly lower in
the group of the 8.1AH carriers, as compared with non-
carriers. One-quarter versus two-thirds, respectively, of 8.1AH
carriers versus non-carriers were found to be colonized.
According to power analysis, sample size was sufficient to
detect a significant difference with 80% power. When only
Table 1. Frequency of the MHC III marker alleles and haplotypes in CF patients and healthy controls









TNF2 (308A) 0.155 0.304*** 0.105 0.118
HSP70-2 1267G (HSP70-2G) 0.420 0.519 0.389 0.427
AGER 429C (AGER-C) 0.181 0286 0.198 0.188
TNF2-HSP70-2G 0.140 0.259*** 0.097 0.072
TNF2-AGER-C 0.104* 0.214** 0.047 0.061
HSP70-2G-AGER-C 0.160 0.259* 0.153 0.137
TNF2-HSP70-2G-AGER-C 0.104* 0.222*** 0.056 0.062
Difference to the healthy controls (Fisher’s exact test), *P < 0.05, **P < 0.01, ***P < 0.001.
Table 2. Data of CF patients (n ¼ 72) stratified according to the 8.1AHa
8.1AH+ (n ¼ 14) 8.1AH (n ¼ 58) P valueb
Male/female 5/9 34/24 0.123
Agec (years) 16.5 (8.3–20.5) 10 (4–17) 0.086
DF508 homozygote/heterozygote 5/9 34/24 0.123
Colonized with Pseudomonas aeruginosa 2 14 0.721
Colonized with Staphylococcus aureus 1 15 0.169
Colonized with P. aeruginosa + S. aureus 1 11 0.437
Colonized total 4 40
0.012Non-colonized 10 18
Age at onset of colonizationc (years)d
DF508 homozygotes 3.0 (1.0–8.0) 14.0, 17.0
DF508 heterozygotes 4.0 (3.0–10.0) 3.0, 18.0
All patients 15.5 (5.4–17.8) 3.0 (0.8–8.0) 0.036
aNumber and median age of patients are shown. bMann–Whitney test or v2 test. cMedian age (25–75% percentile). dOnly patients already
colonized were included.
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patients already colonized were included, the median length
of colonization-free period was more than five times longer in
8.1AH carriers (P = 0.036) (Table 2).
These differences obtained at univariate analysis could be
confirmed by multiple logistic regression analysis. In a multi-
variate logistic regression model, adjusted for age, gender
and DF508 genotype, odds ratio (95% confidence interval) to
be colonized of the carriers versus non-carriers of the 8.1AH
was 0.112 (0.024–0.520; P = 0.005) (Table 3).
The only CF patient who was homozygous for the 8.1AH got
colonized at the age of 17, despite the fact that this patient was
DF508 homozygous.
Comparison of the differences between the 8.1AH carriers
and non-carriers by survival analysis
The colonization-free periods in the groups were compared by
survival analysis, Mantel–Haenszel log rank test. When both
groups of CF patients were analyzed together, in carriers of the
8.1AH the difference in the length of colonization-free period
was found to be highly significant (P < 0.0001) (Fig. 1a). In
DF508 homozygous CF patients who carried the 8.1AH, we
observed significantly longer period free of colonization with
S. aureus and/or P. aeruginosa (P = 0.029) compared with
non-carriers (Fig. 1b). In patients heterozygous for DF508, the
length of colonization-free period was also significantly longer
in carriers of the 8.1AH than in non-carriers (P = 0.004) (Fig. 1c).
Curves ending vertically indicate that DF508 homozygous
patients, both carriers and non-carriers of the 8.1AH, get
colonized by the time they reach the oldest age the curves
indicate in Fig. 1(b). On the contrary, by curves ending
horizontally, Fig. 1(a and c) reflects that in the overall CF
population and in DF508 heterozygotes, those at the oldest
age indicated by the curves are not all colonized.
Most of the data published refer to CF patients with
P. aeruginosa colonization. Therefore, in the next step, we
restricted the analysis to patients who are colonized with
P. aeruginosa. As colonization is a process, the first colonizing
strain is not solely P. aeruginosa, but all patients in this group
are positive for P. aeruginosa. A tendency similar to the
previous ones was observed; the difference between the
carriers and non-carriers of the 8.1AH was significant, too,
when colonization-free period was compared in the 31 CF
patients who were positive for P. aeruginosa (P = 0.025, data
not shown).
Discussion
The novel observation of the present study is that carriership
of the 8.1AH is associated with low frequency and markedly
delayed onset of colonization with both S. aureus and
P. aeruginosa in CF patients. Interestingly, the one and only CF
patient who was homozygous for the 8.1AH became colonized
at the age of 17, despite the fact that this patient was DF508
homozygous. No genetic factor which is thus strongly related
to the time of colonization has been described so far. Recently
De Rose et al. (26) reported on a related observation: they
found homozygous R/R carriers of the Fc gamma receptor IIA
gene associated with increased risk of infection by encapsu-
lated organisms more frequently in CF patients with chronic
P. aeruginosa infection than in uninfected patients or the
general population; the differences were, however, much less
Fig. 1. Colonization-free period in (a) CF patients homozygous and
heterozygous for DF508 (n ¼ 72), (b) DF508 homozygous CF patients
(n ¼ 39) and (c) DF508 heterozygous CF patients (n ¼ 33), carrying
(solid line) and not carrying (broken line) the 8.1AH. A significant
difference is present between the two groups of patients; (a) P <
0.0001, (b) P ¼ 0.029, (c) P ¼ 0.004 (Mantel–Haenszel log rank test).
Table 3. Strength of association with colonization of the 8.1AH





Unadjusted 0.180 (0.050–0.651) 0.009
Adjusted to age and gender 0.100 (0.022–0.455) 0.003
Adjusted to age, gender
and DF508 genotype
0.112 (0.024–0.520) 0.005
a8.1AH carriers versus non-carriers.
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significant (P = 0.042) than those with the 8.1AH in our present
study.
Our present findings indicate that carriage of 8.1AH may
influence the clinical course of CF, and determination of the
8.1AH could be used in clinical practice for predicting
progression rate of CF patients. On the other hand, vaccin-
ation against P. aeruginosa was shown to prevent or to delay
acquisition of bacteria, and to preserve lung function by, at
least in part, induction of antibodies with higher binding affinity
(27). Our observations may contribute to application of
vaccines by categorizing CF patients into high-risk and low-
risk groups in terms of infection, and may account for changes
in therapy and immune prophylaxis. Due to the pathophysi-
ology of the disease—the presence of thick mucus in the
airways—CF patients are immunochallenged without being
immunocompromised; thus, deviations in the genetically en-
coded features of the immune response may result in detect-
able differences concerning infections.
Host–pathogen interactions are crucial in the defense
against infections. Though we cannot give a definite explan-
ation for the delayed onset of colonization in the carriers of the
8.1AH, our present observation, however, is in line with several
reported characteristics of the haplotype. Carriers of the
8.1AH have a genetically determined alteration in immune
response; that is, this haplotype, besides an increased
susceptibility to autoimmune diseases, is thought to confer
resistance to infections (20, 21). The 8.1AH has been partly
characterized by the presence of certain MHC class I and II
alleles that, because of their unique role in antigen pre-
sentation and processing, were important targets of studies on
modifier genes in CF. Since one of these putative alleles, TNF2,
is associated with the 8.1AH in only about 60% of the
population, our findings may contribute to a better un-
derstanding of the conflicting results that were reported on
the association between TNF2 allele alone and markers of
disease severity in CF patients (3–8). These data may also
emphasize the importance of haplotype analysis rather than
determination of SNPs as modifier factors, as previously
suggested by others in the context of disease association
studies (27–29). All known features of the 8.1AH, that is,
increased TNF-a production, deficient handling of circulating
immune complexes and peculiarities in antigen presentation
and processing and antibody production (18, 20, 21), may
influence the effectivity of the defense against different
microorganisms. In this study, CF served as a model for
increased susceptibility to infection. Thus, the data we have
shown here for colonization in CF patients may be applicable
for infectious complications in other diseases, such as sepsis
or chronic obstructive pulmonary disease.
We are aware that our results need confirmation; further
studies involving different countries are essential to test this
hypothesis. However, if our present findings are reproducible,
by the help of determining the carriage of the 8.1AH, CF
patients could be divided into low-risk and high-risk groups,
in terms of colonization. This could be useful for a better
stratification in several immunological, microbiological and
pharmaceutical studies in CF concerning infection, coloniza-
tion as targets. As the geographical distribution of the DF508
allele shows similar pattern to that of the 8.1AH in Europe (30,
31), extended studies may have a chance to clarify whether
during evolution the 8.1AH (as a selection advantage in
carriers of the DF508 allele) could contribute to the mainten-
ance of CF. In addition, findings of this study may have great
relevance to newborn screening for CF.
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CFTR cystic fibrosis transmembrane conductance
regulator
MHC major histocompatibility complex
SNP single-nucleotide polymorphism
TNF-a tumor necrosis factor-a
References
1 Ratjen, F. and Doring, G. 2003. Cystic fibrosis. Lancet 361:681.
2 Koch, C. and Hoiby, N. 1993. Pathogenesis of cystic fibrosis.
Lancet 341:1065.
3 Davies, J. C., Griesenbach, U. and Alton, E. 2005. Modifier genes
in cystic fibrosis. Pediatr. Pulmonol. 39:383.
4 Acton, J. D. and Wilmott, R. W. 2001. Phenotype of CF and the
effects of possible modifier genes. Paediatr. Respir. Rev. 2:332.
5 Lester, L. A., Kraut, J., Lloyd-Still, J. et al. 1994. Delta F508
genotype does not predict disease severity in an ethnically diverse
cystic fibrosis population. Pediatrics 93:114.
6 Hull, J. and Thomson, A. H. 1998. Contribution of genetic factors
other than CFTR to disease severity in cystic fibrosis. Thorax
53:1018.
7 Yarden, J., Radojkovic, D., De Boeck, K. et al. 2005. Association of
tumour necrosis factor alpha variants with the CF pulmonary
phenotype. Thorax 60:320.
8 Arkwright, P. D., Pravica, V., Geraghty, P. J. et al. 2003. End-organ
dysfunction in cystic fibrosis: association with angiotensin I con-
verting enzyme and cytokine gene polymorphisms. Am. J. Respir.
Crit. Care Med. 167:384.
9 The Cystic Fibrosis Genotype-Phenotype Consortium. 1993.
Correlation between genotype and phenotype in patients with
cystic fibrosis. N. Engl. J. Med. 329:1308.
10 Burke, W., Aitken, M. L., Chen, S. H. and Scott, C. R. 1992. Variable
severity of pulmonary disease in adults with identical cystic fibrosis
mutations. Chest 102:506.
11 Arkwright, P. D., Laurie, S., Super, M. et al. 2000. TGF-beta(1)
genotype and accelerated decline in lung function of patients with
cystic fibrosis. Thorax 55:459.
12 Garred, P., Pressler, T., Madsen, H. O. et al. 1999. Association of
mannose-binding lectin gene heterogeneity with severity of lung
disease and survival in cystic fibrosis. J. Clin. Invest. 104:431.
13 Gabolde, M., Guilloud-Bataille, M., Feingold, J. and Besmond, C.
1999. Association of variant alleles of mannose binding lectin with
severity of pulmonary disease in cystic fibrosis: cohort study.
Br. Med. J. 319:1166.
14 Texereau, J., Marullo, S., Hubert, D. et al. 2004. Nitric oxide
synthase 1 as a potential modifier gene of decline in lung function
in patients with cystic fibrosis. Thorax 59:156.
15 Aron, Y., Polla, B. S., Bienvenu, T. et al. 1999. HLA class II
polymorphism in cystic fibrosis. A possible modifier of pulmonary
phenotype. Am. J. Respir. Crit. Care Med. 159:1464.
MHC haplotype, infection and cystic fibrosis 1589
Downloaded from https://academic.oup.com/intimm/article-abstract/18/11/1585/721836
by Hungary EISZ Consortium user
on 19 February 2018
16 Duthie, A., Doherty, D. G., Donaldson, P. T. et al. 1995. The major
histocompatibility complex influences the development of chronic
liver disease in male children and young adults with cystic fibrosis.
J. Hepatol. 23:532.
17 Rubin, B. K. 1990. Exposure of children with cystic fibrosis to en-
vironmental tobacco smoke. N. Engl. J. Med. 323:782.
18 Price, P., Witt, C., Allcock, R. et al. 1999. The genetic basis for
the association of the 8.1 ancestral haplotype (A1, B8, DR3)
with multiple immunopathological diseases. Immunol. Rev.
167:257.
19 Tay, G. K., Cattley, S. K., Chorney, M. J. et al. 1997. Conservation of
ancestral haplotypes telomeric of HLA-A. Eur. J. Immunogenet.
24:275.
20 Caruso, C., Candore, G., Colonna Romano, G. et al. 2000. HLA,
aging, and longevity: a critical reappraisal. Hum. Immunol.
61:942.
21 Candore, G., Modica, M. A., Lio, D. et al. 2003. Pathogenesis of
autoimmune diseases associated with 8.1 ancestral haplotype:
a genetically determined defect of C4 influences immuno-
logical parameters of healthy carriers of the haplotype. Biomed.
Pharmacother. 57:274.
22 Ahmad, T., Armuzzi, A., Neville, M. et al. 2003. The contribution of
human leucocyte antigen complex genes to disease phenotype in
ulcerative colitis. Tissue Antigens 62:527.
23 Hudson, B. I., Stickland, M. H., Futers, T. S. and Grant, P. J. 2001.
Effects of novel polymorphisms in the RAGE gene on transcrip-
tional regulation and their association with diabetic retinopathy.
Diabetes 50:1505.
24 Vargas-Alarcon, G., Londono, J. D., Hernandez-Pacheco, G. et al.
2002. Heat shock protein 70 gene polymorphisms in Mexican
patients with spondyloarthropathies. Ann. Rheum. Dis. 61:48.
25 Schroeder, S., Reck, M., Hoeft, A. and Stuber, F. 1999. Analysis of
two human leukocyte antigen-linked polymorphic heat shock
protein 70 genes in patients with severe sepsis. Crit. Care Med.
27:1265.
26 De Rose, V., Arduino, C., Cappello, N. et al. 2005. Fcgamma
receptor IIA genotype and susceptibility to P. aeruginosa infection
in patients with cystic fibrosis. Eur. J. Hum. Genet. 13:96.
27 Lang, A. B., Horn, M. P., Imboden, M. A. and Zuercher, A. W. 2004.
Prophylaxis and therapy of Pseudomonas aeruginosa infec-
tion in cystic fibrosis and immunocompromised patients. Vaccine
22(Suppl. 1):S44.
28 Degli-Esposti, M. A., Leaver, A. L., Christiansen, F. T. et al. 1992.
Ancestral haplotypes: conserved population MHC haplotypes.
Hum. Immunol. 34:242.
29 Slieker, M. G., Sanders, E. A., Rijkers, G. T., Ruven, H. J. and van
der Ent, C. K. 2005. Disease modifying genes in cystic fibrosis.
J. Cyst. Fibros. 4(Suppl. 2):7.
30 Bobadilla, J. L., Macek, M., Jr, Fine, J. P. and Farrell, P. M. 2002.
Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation
with incidence data and application to screening. Hum. Mutat.
19:575.
31 Candore, G., Lio, D., Colonna Romano, G. and Caruso, C. 2002.
Pathogenesis of autoimmune diseases associated with 8.1 an-
cestral haplotype: effect of multiple gene interactions. Autoimmun.
Rev. 1:29.
1590 MHC haplotype, infection and cystic fibrosis
Downloaded from https://academic.oup.com/intimm/article-abstract/18/11/1585/721836
by Hungary EISZ Consortium user
on 19 February 2018
